Community oncology practices are the backbone of cancer care in the United States, providing treatment to about 80% of all patients with cancer. However, these practices face significant challenges attracting oncology fellows.

For people living with chronic and complex illnesses, consistent treatment access is critical to stay healthy. However, burdensome practices from insurance industry middlemen are creating unnecessary barriers to care for patients and providers alike.

It continues to be an eventful and tumultuous time in the 340B Drug Pricing Program space, with little indication that the current environment will change any time soon. Numerous drug manufacturers continue to impose restrictive 340B pricing policies available via 340B contract pharmacy arrangements in contravention of the Health Resources and Services Administration's (HRSA) applicable 340B Program rules and guidance.

A new bill set to be considered on Wednesday by the House Ways & Means Committee would extend for two years telehealth flexibilities for Medicare enrollees that were adopted during the Covid-19 pandemic, and look to reform drug industry middlemen to pay for it.

Following the unanimous passage of legislation in 2021, the Delaware Department of Insurance was given regulatory authority over Pharmacy Benefit Managers (PBMs) and has been building an investigation and enforcement program in order to address the multi-billion-dollar industry that has played a key role in increasing total cost of care and consolidating the pharmacy market.

In a bid to curtail the ongoing problem of drug shortages, the Senate Finance Committee proposed legislation offering incentives to hospitals and other providers to stockpile certain medications.

In 2020, cancer claimed more than 600,000 lives in the US. Cancer is an unyielding public health crisis. Cancer treatments typically involve multidisciplinary approaches, including surgery, radiation therapy, chemotherapy, and oral medications. For patients, especially those in rural areas, obtaining multiple oral medications can be inconvenient.

WASHINGTON (AP) — The go-broke dates for Medicare and Social Security have been pushed back as an improving economy has contributed to changed projected depletion dates, according to the annual Social Security and Medicare trustees report Monday.

It continues to be an eventful and tumultuous time in the 340B Drug Pricing Program space, with little indication that the current environment will change any time soon. Numerous drug manufacturers continue to impose restrictive 340B pricing policies available via 340B contract pharmacy arrangements in contravention of the Health Resources and Services Administration's (HRSA) applicable 340B Program rules and guidance.